Is DMRA or CGON more profitable?

CG Oncology's return on equity of -23.33% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% CG Oncology N/A -23.33% -22.24%

Is DMRA or XENE more profitable?

Xenon Pharmaceuticals' return on equity of -49.23% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% Xenon Pharmaceuticals N/A -49.23% -46.42%

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

$26.01 +1.80 (+7.43%)

As of 04:00 PM Eastern

Compare

DMRA vs. CGON, LEGN, TWST, XENE, and CRSP

Should you buy Damora Therapeutics, Inc. Common Stock stock or one of its competitors? MarketBeat compares Damora Therapeutics, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Damora Therapeutics, Inc. Common Stock include CG Oncology (CGON), Legend Biotech (LEGN), Twist Bioscience (TWST), Xenon Pharmaceuticals (XENE), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry.

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, CG Oncology had 11 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 12 mentions for CG Oncology and 1 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.89 beat CG Oncology's score of 0.63 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Very Positive
CG Oncology	Positive

Damora Therapeutics, Inc. Common Stock presently has a consensus price target of $42.43, indicating a potential upside of 63.12%. CG Oncology has a consensus price target of $81.73, indicating a potential upside of 15.03%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

CG Oncology's return on equity of -23.33% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
CG Oncology	N/A	-23.33%	-22.24%

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

CG Oncology has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. CG Oncology is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
CG Oncology	$4.04M	1,551.14	-$160.99M	-$2.33	N/A

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

CG Oncology beats Damora Therapeutics, Inc. Common Stock on 9 of the 15 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Legend Biotech had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 3 mentions for Legend Biotech and 1 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.89 beat Legend Biotech's score of 0.94 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Legend Biotech	Positive
Damora Therapeutics, Inc. Common Stock	Very Positive

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Damora Therapeutics, Inc. Common Stock has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.21	-$296.80M	-$0.68	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Legend Biotech has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Legend Biotech presently has a consensus target price of $60.23, suggesting a potential upside of 108.56%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.43, suggesting a potential upside of 63.12%. Given Legend Biotech's higher possible upside, equities research analysts plainly believe Legend Biotech is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Legend Biotech and Damora Therapeutics, Inc. Common Stock tied by winning 8 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Twist Bioscience?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Twist Bioscience	-19.85%	-26.73%	-19.15%

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Twist Bioscience has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Twist Bioscience is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Twist Bioscience	$376.57M	17.01	-$77.67M	-$1.33	N/A

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

In the previous week, Twist Bioscience had 12 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 13 mentions for Twist Bioscience and 1 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.89 beat Twist Bioscience's score of 0.22 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Very Positive
Twist Bioscience	Neutral

Damora Therapeutics, Inc. Common Stock presently has a consensus price target of $42.43, indicating a potential upside of 63.12%. Twist Bioscience has a consensus price target of $79.30, indicating a potential downside of 22.92%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, equities research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Twist Bioscience beats Damora Therapeutics, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Xenon Pharmaceuticals' return on equity of -49.23% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Damora Therapeutics, Inc. Common Stock has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Xenon Pharmaceuticals	$7.50M	778.00	-$345.91M	-$4.70	N/A

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock currently has a consensus target price of $42.43, suggesting a potential upside of 63.12%. Xenon Pharmaceuticals has a consensus target price of $77.20, suggesting a potential upside of 27.90%. Given Damora Therapeutics, Inc. Common Stock's higher probable upside, equities analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 2 mentions for Xenon Pharmaceuticals and 1 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.89 beat Xenon Pharmaceuticals' score of 0.96 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Very Positive
Xenon Pharmaceuticals	Positive

Summary

Xenon Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 9 of the 14 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CRISPR Therapeutics currently has a consensus price target of $67.78, suggesting a potential upside of 24.17%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $42.43, suggesting a potential upside of 63.12%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, CRISPR Therapeutics had 5 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 1 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.89 beat CRISPR Therapeutics' score of 0.64 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
CRISPR Therapeutics	Positive
Damora Therapeutics, Inc. Common Stock	Very Positive

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Damora Therapeutics, Inc. Common Stock has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,499.92	-$581.60M	-$6.22	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Summary

CRISPR Therapeutics and Damora Therapeutics, Inc. Common Stock tied by winning 8 of the 16 factors compared between the two stocks.

Get Damora Therapeutics, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMRA vs. The Competition

Export

Metric	Damora Therapeutics, Inc. Common Stock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.49B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-4.66	20.90	27.51	24.87
Price / Sales	N/A	341.80	540.69	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	-0.24	8.75	11.01	6.54
Net Income	-$209.84M	$23.81M	$3.57B	$336.70M
7 Day Performance	13.38%	3.64%	2.56%	3.31%
1 Month Performance	4.54%	1.64%	0.89%	1.68%
1 Year Performance	662.76%	69.47%	36.84%	31.96%

Damora Therapeutics, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMRA Damora Therapeutics, Inc. Common Stock	3.8203 of 5 stars	$26.01 +7.4%	$42.43 +63.1%	+622.5%	$1.49B	N/A	N/A	40	Positive News
CGON CG Oncology	2.9538 of 5 stars	$65.73 -0.8%	$81.73 +24.3%	+184.1%	$5.84B	$5.07M	N/A	61	News Coverage Insider Trade Options Volume
LEGN Legend Biotech	3.2156 of 5 stars	$29.30 -0.1%	$60.23 +105.6%	-15.1%	$5.45B	$1.03B	N/A	2,965
TWST Twist Bioscience	1.3875 of 5 stars	$85.00 -0.2%	$71.60 -15.8%	+173.8%	$5.30B	$376.57M	N/A	990	Analyst Forecast
XENE Xenon Pharmaceuticals	3.715 of 5 stars	$54.61 -0.3%	$77.20 +41.4%	+85.6%	$5.30B	$7.50M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMRA) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. CGON, LEGN, TWST, XENE, and CRSP

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Legend Biotech?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Twist Bioscience?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to CRISPR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. CGON, LEGN, TWST, XENE, and CRSP

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Does the media favor DMRA or CGON?

Do analysts prefer DMRA or CGON?

Is DMRA or CGON more profitable?

Which has more volatility & risk, DMRA or CGON?

Which has stronger earnings & valuation, DMRA or CGON?

Do institutionals & insiders believe in DMRA or CGON?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Legend Biotech?

Does the media refer more to LEGN or DMRA?

Is LEGN or DMRA more profitable?

Do insiders & institutionals have more ownership in LEGN or DMRA?

Which has preferable earnings and valuation, LEGN or DMRA?

Which has more risk and volatility, LEGN or DMRA?

Do analysts rate LEGN or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Twist Bioscience?

Is DMRA or TWST more profitable?

Do insiders and institutionals have more ownership in DMRA or TWST?

Which has stronger valuation & earnings, DMRA or TWST?

Which has more risk and volatility, DMRA or TWST?

Does the media refer more to DMRA or TWST?

Do analysts recommend DMRA or TWST?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Do institutionals & insiders have more ownership in DMRA or XENE?

Is DMRA or XENE more profitable?

Which has higher valuation and earnings, DMRA or XENE?

Which has more volatility and risk, DMRA or XENE?

Do analysts recommend DMRA or XENE?

Does the media favor DMRA or XENE?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to CRISPR Therapeutics?

Do institutionals and insiders have more ownership in CRSP or DMRA?

Do analysts rate CRSP or DMRA?

Does the media prefer CRSP or DMRA?

Which has more volatility and risk, CRSP or DMRA?

Is CRSP or DMRA more profitable?

Which has preferable earnings and valuation, CRSP or DMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools